
YEARS was noninferior and avoided immediate CT angiography in 22% of cancer patients
AI-summarized from the linked source. Educational brief, not medical advice.
Brief summary
A multicenter randomized noninferiority trial found a YEARS-based diagnostic strategy was as safe as CT pulmonary angiography alone for suspected pulmonary embolism in active cancer and avoided immediate CT imaging in 22% of patients.
What NurseJet pulled from the source
The Hydra trial randomized 698 patients with active cancer and suspected pulmonary embolism at 21 hospitals. Among patients whose PE was ruled out initially, 90-day symptomatic venous thromboembolism or possible PE-related death met the prespecified noninferiority criterion for YEARS versus CTPA-only management. YEARS managed 77 of 352 patients without CTPA.
Why this matters for nurses
Oncology, emergency, and medical-unit nurses frequently initiate assessment and testing workflows for cancer patients with new dyspnea, chest pain, hypoxemia, or other possible PE features. The trial supports protocolized risk assessment while preserving prompt escalation for instability or changing symptoms.
Bedside takeaway
YEARS can reduce immediate CT imaging in eligible cancer patients when used within an approved diagnostic pathway.
How This Applies in Practice
Use this when: Caring for a patient with active cancer who is being evaluated for suspected acute pulmonary embolism.
On your shift
- Escalate hemodynamic instability, hypoxemia, new chest symptoms, or other urgent findings through the PE response pathway.
- Gather and document the clinical assessment elements and ordered D-dimer required by the organization's diagnostic algorithm.
- Confirm that imaging or PE exclusion decisions are completed under the approved pathway and responsible clinician.
Key takeaways
- The trial randomized 698 patients with active cancer and suspected acute pulmonary embolism.
- A YEARS strategy using clinical items, D-dimer, and risk-dependent CTPA met the prespecified noninferiority criterion.
- The YEARS pathway avoided immediate CTPA in 77 of 352 patients, or 22%.
- The proportion of negative CTPA results did not differ significantly between groups.
Practice implications
- Recognize and escalate possible PE promptly, collect the clinical information and ordered D-dimer needed for the approved pathway, and verify whether the organization permits YEARS in active cancer. Do not use the trial to independently rule out PE or defer imaging outside protocol.
Limitations & cautions
- The study was open label, applied a prespecified noninferiority margin, and was conducted in 21 European hospitals. The result supports the tested pathway in eligible patients but does not validate unsupervised bedside use or every cancer population.
- AI-summarized from the linked source. Review the original article before applying to practice.
Citations
Exact source links
Public citations are filtered to exact credible source pages. Homepage-only or invalid links stay in admin review and are not shown here.
JAMA (PubMed)
JAMA (PubMed). YEARS Algorithm for Diagnosis of Suspected Pulmonary Embolism in Patients With Cancer: A Randomized Clinical Trial.
https://pubmed.ncbi.nlm.nih.gov/42437322/
Professional education only


